Welcome!

News Feed Item

Easton Pharmaceuticals Announces Legal Action Against Seeking Alpha Writer as a Response to Libelous Article

TORONTO, ON -- (Marketwired) -- 07/08/14 -- Easton Pharmaceuticals (OTC: EAPH) announces corporate response to libelous seeking alpha article.

As a response to a second seeking alpha written by a Mr. Matt Finston, Easton Pharmaceuticals has entered in discussions to join with 1 to 2 other companies in a joint legal response to Matt Finston and articles written and posted by him on seeking alpha against Easton Pharmaceuticals and these other companys.

As disclosed in a prior press release, Easton Pharmaceuticals was the victim of a slanderous article by a Matt Finston of seeking alpha posted in March of 2014. It has now come to the company's attention that a second article attacking the company was once again posted today. The writer, Mr. Matt Finston and seeking alpha who normally only post or write on mid to large cap stocks, posted an article on the Company that was not only once again inaccurate, but made libelous allegations against its products and others involved in the company. The second article on Easton Pharmaceuticals, released this morning has once again been released after a recent uptrend in the companies trading stock. Both times the articles were followed by massive short or negative posts on many investor chat boards in an attempt to dis-credit the company. The most recent article goes to great lengths to cause as much damage as possible to the company which is thought by the company's attorney as well as by others to be out of the ordinary. As a response to this clear attempt to hurt shareholders and the companies attempt to grow its business, Easton believes it will soon join with other companies who have either sued Mr. Finston as a response to similar attacks or are in the process of launching lawsuits. Mr. Finston has not only repeatedly stated the incorrect cash position of the company, the wrong names for the company's directors, but has also posted the wrong names of products or posted that the company still owns products that were previously sold. Other information was also mentioned in the article including allegations that the company has been involved with other websites to promote the company's common stock which is vehemently denied by the company. This is a clear attempt to purposely provide mis-leading and libelous information in an attempt to assist in possibly shorting the company's common stock by any means necessary. Through its attorneys, Easton Pharmaceuticals will make every attempt to defend itself against these types of attacks.

To clarify and correct the deliberate mis-statements made by Mr. Finston, Currently Easton Pharmaceuticals owns or co-owns products, patents or patents pending regarding its delivery system, some of which are incorporated into several OTC products and Drugs it co-owns. Included is a drug co-owned with a private Canadian pharmaceutical company for the treatment of FSAD (female sexual arousal disorder) which previously underwent testing at Cedar Sinai Medical Center in Beverly Hills, CA. The testing program was prematurely halted but was not as a result of lack of efficacy. Easton Pharmaceuticals originally owned an FDA drug to help treat wounds, known as the L.A.M. IPM Wound Gel. This product was approved by the FDA and deemed by the FDA to be 88% effective in treating wounds. In 2009, previous management made the decision to sell the IPM Wound gel and focus on other products such as Viorra. Although delays have been met by the company in the last 2 to 3 years and the product Viorra has been progressing more slowly than expected due to various reasons including the company's entrance into the medical marijuana industry, Viorra and other products are close to being made available for sale and purchase, notwithstanding any unforeseen impediments.

Through the assistance of consultants and its Philadelphia based attorney, Easton previously signed LOI's and were in negotiations for various medical marijuana initiatives in the State Of Colorado and other states. The Colorado initiatives have since been abandoned for various reasons including the fact medical marijuana is still federally illegal which would cause legal issues for a public company who is involved in growops. Instead, the Company, as previously announced, has signed an exclusive option agreement to purchase up to 50% ownership in a private Canadian Medical Marijuana Company that is near completing its facilities build-out and awaiting its final inspection with health Canada to obtain a growers license for the entire country of Canada. Currently only 13 companies have obtained growers licenses and only 48 have received letters to build.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact:

Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email:
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
In his session at 20th Cloud Expo, Brad Winett, Senior Technologist for DDN Storage, will present several current, end-user environments that are using object storage at scale for cloud deployments including private cloud and cloud providers. Details on the top considerations of features and functions for selecting object storage will be included. Brad will also touch on recent developments in tiering technologies that deliver single solution and an end-user view of data across files and objects...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, discussed how AI can simplify cloud operations. He covered the following topics: why cloud mana...
"I will be talking about ChatOps and ChatOps as a way to solve some problems in the DevOps space," explained Himanshu Chhetri, CTO of Addteq, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching o...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settl...
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...